Skip to main content
. 2015 Jul 31;16(9):1145–1163. doi: 10.15252/embr.201540759

Figure 8.

Figure 8

BNIP3 is deleted in human triple-negative breast cancer and predicts reduced metastasis-free survival

  1. Hormone receptor status (red = positive, black = negative) and chromosomal copy number variation (CNV, as defined by the GISTIC algorithm) of BNip3 (red = gain greater than or equal to 1, blue = loss less than or equal to −1, white = unchanged) from n = 689 patient samples in The Cancer Genome Atlas (TCGA) breast cohort where status is unambiguously assigned for all three hormone receptors and copy number data are available and assigned by the GISTIC algorithm.
  2. Relative frequency of copy number variation (CNV) of BNip3 in triple-negative breast cancer (TNBC; red, n = 113) and non-TNBC (black, n = 576) in TCGA breast cohort.
  3. TNBC patient metastasis-free survival in low-BNip3-expressing patients (below median, n = 51) stratified by high (above median) and low (below median) expressing Hif-1α.
  4. TNBC patient metastasis-free survival in high-BNip3-expressing patients (above median, n = 50) stratified by high (above median) and low (below median) expressing Hif-1α.
  5. Schematic summary of the role of BNIP3 in suppressing tumor progression and metastasis.